Switching off renal inflammation by anti-inflammatory mediators: The facts, the promise and the hope

Kidney International

Volumn 53, Issue 5, 1998, Pages 1118-1126

  Baud, Laurent ^a   Fouqueray, Bruno ^a   Bellocq, Agnés ^a  

^a HÔPITAL TENON   (France)

Author keywords

Cell repair; Fibrosis; Glomerulonephritis; Glucocorticoids; Immune response; Interleukins

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4;

ANTIINFLAMMATORY ACTIVITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; HUMAN; NEPHRITIS; PRIORITY JOURNAL; REVIEW;

EID: 0031846190     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00877.x     Document Type: Article

References (108)

1. HUANG XR, LEECH M, TIPPING PG, HOLDSWORTH SR: Endogenous corticosteroids inhibit acute neutrophil mediated glomerulonephritis in rats, (abstract) Nephrology 1 (Suppl):S486, 1997
2. BADR KF: Arachidonate cyclo-oxygenase and lipoxygenase products in the mediation of glomerular immune injury. Nephrol Dial Transplant 6:662-669, 1991
3. 4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int 47:1295-1302, 1995
4. MAYADAS TN, MENDRICK DL, BRADY HR, TANG T, PAPAYIANNI A, ASSMANN KJM, WAGNER DD, HYNES RO, COTRAN RS: Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice. Kidney Int 49:1342-1349, 1996
5. 4 by platelet 12-lipoxygenase in vitro. J Clin Invest 85:772-780, 1990
6. BADR KF: 15-lipoxygenase products as leukotriene antagonists: Therapeutic potential in glomerulonephritis. Kidney Int 42(Suppl 38):S101-S108, 1992
7. BRADY HR, PERSSON U, BALLERMANN BJ, BRENNER BM, SERHAN CN: Leukotrienes stimulate neutrophil adhesion to mesangial cells: Modulation with lipoxins. Am J Physiol 259:F809-F815, 1990
8. 4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 156:2264-2272, 1996
9. 4 in rat glomerular mesangial cells: Evidence for competition at a common receptor. Proc Natl Acad Sci USA 86:3438-3442, 1989
10. BREZINSKI ME, SERHAN CN: Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: Agonist-induced deacylation and transformation of stored hydroxyeicosanoids. Proc Natl Acad Sci USA 87:6248-6252, 1990
11. 4 in the rat. Kidney Int 41:1155-1160, 1992
12. YURA T, FUKUNAGA M, MUNGER KA, IMAI E, BADR KF: In vivo transfection of human arachidonate 15-lipoxygenase gene into the rat kidney: Impact on nephrotoxic serum nephritis. (abstract) J Am Soc Nephrol 6:890, 1995
13. 4 are potent stimuli for human monocyte migration and adhesion: Selective inactivation by dehydrogenation and reduction. J Exp Med 183:137-146, 1996
14. NASSAR GM, MONTERO A, FUKUNAGA M, BADR KF: Contrasting effects of pro-inflammatory and T-helper lymphocyte subset-2 cytokines on the 5-lipoxygenase pathway in monocytes. Kidney Int 51:1520-1528, 1997
15. CONRAD DJ, KUHN H, MULKINS M, HIGHLAND E, SIGAL E: Specilic inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc Natl Acad Sci USA 89:217-221, 1992
16. COLOTTA F, RE F, MUZTO M, BERTINI R, POLENTARUTTI N, SIRONI M. GIRI JG, DOWER SK, SIMS JE, MANTOVANI A: Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 261:472-475, 1993
17. COLOTTA F, RE F, MUZIO M, POLENTARUTTI N, MINTY A, CAPUT D, FERRARA P, MANTOVANI A: Interleukin-13 induces expression and release of interleukin-1 decoy receptor in human polymorphonuclear cells. J Biol Chem 269:12403-12406, 1994
18. COLOTTA F, SACCANI S, GIRI JG, DOWER SK, SIMS JE, INTRONA M, MANTOVANI A: Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes. J Immunol 156:2534-2541, 1996
19. DE WAAL MALEFYT R, FIGDOR CG, HUIJBENS R, MOHAN-PETERSON S. BENNETT B, CULPEPPER J, DANG W, ZURAWSKI G, DE VRIES JE: Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-γ or IL-10. J Immunol 151:6370-6381, 1993
20. KATOH T, LAKKIS FG, MAKITA N, BADR KF: Co-regulated expression of glomerular 12/15 lipoxygenase and interleukin-4 mRNAs in rat nephrotoxic nephritis. Kidney Int 46:341-349, 1994
21. LAKKIS FG, BADDOURA FK, CRUET EN, PAREKH KR, FUKUNAGA M, MUNGER KA: Anti-inflammatory lymphokine mRNA expression in antibody-induced glomerulonephritis. Kidney Int 49:117-126, 1996
22. LAKKIS FG, CRUET EN: Cloning of rat interleukin-13 (IL-13) cDNA and analysis of IL-13 gene expression in experimental glomerulonephritis. Biochem Biophys Res Commun 197:612-618, 1993
23. PENNY MJ, BOYD RA, HALL BM: Role of T cells in the mediation of Heymann nephritis. II. Identification of Th1 and cytotoxic cells in glomeruli. Kidney Int 51:1059-1068, 1997
24. BFSSIS N, BOISSIER MC, FERRARA P, BLANKENSTEIN T. FRADELIZI D. FOURNIER C: Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 26:2399-2403, 1996
25. TAM FWK, SMITH J, KARKAR AM, PUSEY CD, REES AJ: Interleukin-4 ameliorates experimental glomerulonephritis and up-regulates glomerular gene expression of IL-1 decoy receptor. kidney Int 52:1224-1231, 1997
26. TIPPING PG, KITCHING AR, HUANG XR, MUTCH DA, HOLDSWORTH SR: Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol 27:530-537, 1997
27. KITCHING AR, TIPPING PG, HUANG XR, MUTCH DA. HOLDSWORTH SR: Interleukin-4 and interleukin-10 attenuate established crescentic glomerulonephritis in mice. Kidney Int 52:52-59, 1997
28. SANTIAGO M-L, FOSSATI L, JACQUET C, MÜLLER W, IZUI S, REININGER L: Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. J Exp Med 185:65-70, 1997
29. + T cell infiltration. j Immunol 149:2954-2960, 1992
30. POSTLETHWAITE AE, HOLNESS MA, KATAI H, RAGHOW R: Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 90:1479-1485, 1992
31. NAKAZATO Y, OKADA H, TAJIMA S, HAYASHIDA T, KANNO Y, SUZUKI H. SARUTA T: Interleukin-4 modulates collagen synthesis by human mesangial cells in a type-specific manner. Am J Physiol 270:F447-F453, 1996
32. PATTERSON PH: Leukemia inhibitory factor, a cytokine at the interface between neurobiology and immunology. Proc Natl Acad Sci USA 91:7833-7835, 1994
33. TANG WW, OI M, VAN GY, WARINER GP, SAMAL B: Leukemia inhibitory factor ameliorates experimental anti-GBM Ah glomerulonephritis. Kidney Int 50:1922-1927, 1996
34. HARTNER A, STERZEL RB, REINDL N, HOCKE GM, FEY GH, GOPPELT-STRUEBE M: Cytokine-induced expression of leukemia inhibitory factor in renal mesangial cells. Kidney Int 45:1562-1571, 1494
35. HORII Y, IWANO M, HIRATA E, SHIIKI H, FUJII Y. DOHI K, ISHIKAWA H: Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int 43(Suppl 39):S7I-S75, 1993
36. RANIERI E, GESUALDO L, PETRARULO F, SCHENA FP: Urinary IL-6/EGF ratio: A useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int 50:1990-2001, 1996
37. HORII Y, MURAGUCHI A, IWANO M, MATSUDA T, HIRAYAMA T, YAMADA H, FUJII Y, DOHI K, ISHIKAWA H, OHMOTO Y, YOSHIZAKI K, HIRANO T, KISHIMOTO T: Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol 143:3949-3955, 1989
38. HEIDENREICH S, SATO T, SCHMIDT M, AUGUST C, TIMMERMAN JJ, VAN Es LA, DAHA MR: Induction of mesangial interleukin-6 synthesis by apoptotic U 937 cells and monocytes. Kidney Int 52:318-328, 1997
39. VAN DEM DOBBELSTEEN MEA, VAN DER WOUDE FJ, SCHROEIJERS WEM, VAN ES LA, DAHA MR: Soluble aggregates of IgG and immune complexes enhance IL-6 production by renal mesangial cells. Kidney Int 43:544-553, 1993
40. VAN DEN DOBBELSTEEN MEA, VAN DER WOUDE FJ, SCHROEIJERS WEM, VAN DEN WALL BAKE AWL, VAN ES LA. DAHA MR: Binding of dimeric and polymeric IgA to rat renal mesangial cells enhances the release of interleukin-6. Kidney Int 46:512-519, 1994
41. EITNER F, WESTERHUIS R, BURG M, WEINHOLD B, GRÖSE H-J, OSTENDORF T, RÜTHER U, KOCH K-M, REES AJ, FLOEGE J: Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney Int 51:69-78, 1997
42. IKEDA M, IKEDA U, OHARA T, KUSANO E, KANO S: Recombinant interleukin-6 inhibits the growth of rat mesangial cells in culture. Am J Pathol 141:327-334, 1992
43. LE J, VILCEK J: Interleukin-6: A multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 61:588-602, 1989
44. TILG H, TREHU E, ATKINS MB, DINARELLO CA, MIER JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p 55. Blood 83:113-118, 1994
45. KARKAR AM, TAM FWK, PROUDFOOT AEI, MEAGER A, REES AJ: Modulation of antibody-mediated glomerular injury in vivo by interleukin-6. Kidney Int 44:967-973, 1993
46. KARKAR AM, SMITH J, TAM FWK, PUSEY CD, REES AJ: Abrogation of glomerular injury in nephrotoxic nephritis by continuous infusion of interleukin-6. Kidney Int 52:1313-1320, 1997
47. MONTINARO V, HEVEY K, AVENTAGGIATO L, FADDEN K, ESPARZA A, CHEN A, FINBLOOM DS, RIFAI A: Extrarenal cytokines modulate the glomerular response to IgA immune complexes. Kidney Int 42:341-353, 1992
48. NAITO T, YOKOYAMA H, MOORE KJ, DRANOFF G, MULLIGAN RC, RUBIN KFLLEY V: A gene transfer system establishes interleukin-6 neither promotes nor suppresses renal injury. Am J Physiol 271:F603-F609, 1996
49. RYFFEL B, CAR BD, GUNN H, ROMAN D, HIESTAND P, MIHATSCH MJ: Interleukin-6 exacerbates glomerulonephritis in (NZBxBZW) F1 mice. Am J Pathol 144:927-937, 1994
50. TREPICCHIO WL, BOZZA M, PEDNEAULT G, DORNER AJ: Recombinant human IL-11 attenuates the inflammatory response through down-regulation of pro-inflammatory cytokine release and nitric oxide production. J Immunol 157:3627-3634, 1996
51. MOORE KW, O'GARRA A, DE WAAL MALEFYT R, VIEIRA P, MOSMANN TR: Interleukin-10. Annu Rev Immunol 11:165-190, 1993
52. FOUQUERAY B, BOUTARD V, PHILIPPE C, KORNEICH A, MARCHANT A, PEREZ J, GOLDMAN M, BAUD L: Mesangial cell-derived intrleukin-10 modulates mesangial cell response to lipopolysaccharide. Am J Pathol 147:176-182, 1995
53. WANIDVORANUN C, STROBER W: Predominant role of tumor necrosis factor-α in human monocyte IL-10 synthesis. J Immunol 151:6853-6861, 1993
54. 2. J Exp Med 180:2365-2370, 1994
55. SUBERVILLE S, BELLOCO A, FOUQUERAY B, PHILIPPE C, LANTZ O, PEREZ J, BAUD L: Regulation of interleukin-10 production by β-adrenergic agonists. Eur J Immunol 26:2601-2605, 1996
56. MAEDA H, KUWAHARA H, ICHIMURA Y, OHTSUKI M, KURAKATA S, SHIRAISHI A: TGF-β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J Immunol 155:4926-4932, 1995
57. DE WAAL MALEFYT R, ABRAMS J, BENNETT B, FIGDOR CG, DE VRIES JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209-1220, 1991
58. PRADIER O, GÉRARD C, DELVAUX A, LYBIN M. ABRAMOVICZ D, CAPEL P, VELU T, GOLDMAN M: Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur J Immunol 23:2700-2703, 1993
59. MERTZ PM, DE WITT DL, STETLER-STEVENSON WG, WAHL LM: Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metal-loproteinase production. J Biol Chem 269:21322-21329, 1994
60. CASSATELLA MA, MEDA L, BONORA S, CESKA M, CONSTANTIN G: Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 178:2207-2211, 1993
61. VORA M, ROMERO LI, KARASEK MA: Interleukin-10 induces E-selectin on small and large blood vessel endothelial cells. J Exp Med 184:821-829, 1996
62. WILLEMS F, MARCHANT A, DELVILLE J-P, GERARD C, DELVAUX A, VELU T, DE BOER M, GOLDMAN M: Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 24:1007-1009, 1994
63. GIOVARELLI M, MUSIANI P, MODESTI A, DELLABONA P, CASORATI G, ALLIONE A, CONSALVO M, CAVALLO F, DI PIERRO F, DE GIOVANNI C, MUSSO T, FORNI G: Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 155:3112-3123, 1995
64. BERMAN RM, SUZUKI T, TAHARA H, ROBBINS PD, NARULA SK, LOTZE MT: Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 157:231-238, 1996
65. CHADBAN SJ, TESCH GH, FOTI R, ATKINS RC, NIKOLIC-PATERSON DJ: Interleukin-10 is a mesangial cell growth factor in vitro and in vivo. Lab Invest 76:619-627, 1997
66. FOUQUERAY B, SUBERVILLE S, ISAKA Y, AKAGI Y, GERARD C, VELU T, IMAI E, BAUD L: Reduction of proteinuria in anti-glomerular basement membrane nephritis by interleukin (IL)-10 gene transfer, (abstract) J Am Soc Nephrol 7:1698, 1996
67. KITAMURA M, TAYLOR S, UNWIN R, BURTON S, SHIMIZU F, FINE LG: Gene transfer into the rat renal glomerulus via a mesangial cell vector: Site-specific delivery, in situ amplification, and sustained expression of an exogenous gene in vivo. J Clin Invest 94:497-505. 1994
68. ISAKA Y, BREES DK, IKEGAYA K, KANEDA Y, IMAI E, NOBLE NA, BORDER WA: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 2:418-423, 1996
69. CHADBAN SJ, TESCH GH, LAN HY, ATKINS RC, NIKOLIC-PATERSON DJ: Effect of interleukin-10 treatment on crescentic glomerulonephritis in rats. Kidney Int 51:1809-1817, 1997
70. ISHIDA H, MUCHAMUEL T, SAKAGUCHI S, ANDRADE S, MENON S, HOWARD M: Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 179:305-310, 1994
71. AREND WP: Inteleukin-1 receptor antagonist. Adv Immunol 54:167-227, 1993
72. TAM FWK, SMITH J, CASHMAN SJ, WANG Y, THOMPSON EM, REES AJ: Glomerular expression of interleukin-1 receptor antagonist and interleukin-1β genes in antibody-mediated glomerulonephritis. Am J Pathol 145:126-136, 1994
73. KARKAR AM, TAM FWK, STEINKASSERER A, KURRLE R, LANGNER K, SCALLON BJ, MEAGER A, REES AJ: Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1receptor. and soluble TNF receptor. Kidney Int 48:1738-1746, 1995
74. NIKOLIC-PATERSON DJ, LAN HY, HILL PA, VANNICE JL, ATKINS RC: Suppression of experimental glomerulonephritis by the interleukin-1 receptor antagonist: Inhibition of intercellular adhesion molecule-1 expression. J Am Soc Nephrol 4:1695-1700, 1994
75. LAN HY, NIKOLIC-PATERSON DJ, ZARAMA M, VANNICE JL, ATKINS RC: Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int 43:474-485, 1993
76. LAN HY, NIKOLIC-PATERSON DJ, MU W. VANNICE JL, ATKINS RC: Inteleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Kidney Int 47:1303-1309, 1995
77. MAKAROV SS, OLSEN JC, JOHNSTON WN, ANDERLE SK, BROWN RR, BALDWIN AS, HASKILL JS, SCHWEB JH: Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci USA 93:402-406, 1996
78. YOKOO T, KITAMURA M: Gene transfer of interleukin-1 receptor antagonist into the renal glomerulus via a mesangial cell receptor. Biochem Biophys Res Commun 226:883-888, 1996
79. FERNANDEZ-BOTRAN R: Soluble cytokine receptors: Their role in immunoregulation. FASEB J 5:2567-2574, 1991
80. RE F, SIRONI M, MUZIO M, MATTEUCI C, INTRONA M, ORLANDO S, PENTON-ROL G, DOWKR SK, SIMS JE, COLOTTA F, MANTOVANI A: Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: A surface "receptor" with anti-interleukin-1 function. J Exp Med 183:1841-1850, 1996
81. ORLANDO S, MATTEUCCI C, FADLON EJ, BUURMAN WA, BARDELLA MT, COLOTTA F, INTRONA M, MANTOVANI A: TNF-α. unlike other pro- and anti-inflammatory cytokines, induces rapid release of the IL-1type II decoy receptor in human myelomonocytic cells. J Immunol 158:3861-3868, 1997
82. BURGER D, CHICHEPORTICHE R, GIRI JG, DAYER J-M: The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 96:38-41, 1995
83. WILLIAMS LM, GIBBONS DL, GEARING A, MAINI RN, FELDMANN M. BRENNAN FM: Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both P55 and P75 TNF receptor shedding and TNFα processing in RA synovial membrane cell cultures. J Clin Invest 97:2833-2841, 1996
84. VAN ZEE KJ, KOHNO T. FISCHER E, ROCK CS, MOLDAWER LL, LOWRY SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo. Proc Natl Acad Sci USA 89:4845-4849, 1992
85. ADERKA D, ENGELMANN H, MAOR Y, BRAKEBUSCH C, WALLACH D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323-329, 1992
86. MULLIGAN MS, JOHNSON KJ, TODD RF, ISSEKUTZ TB, MIYASAKA M, TAMATANI T, SMITH CW, ANDERSON DC, WARD PA: Requirements for leukocyte adhesion molecules in nephrotoxic nephrilis. J Clin Invest 91:577-587, 1993
87. ASHKENAZI A, MARSTERS SA, CAPON DJ, CHAMOW SM, FIGARI IS, PENNICA D, GOEDDEL DV, PALLADINO MA, SMITH DH: Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 88:10535-10539, 1991
88. TSUNAWAKI S, SPORN M, DING, A, NATHAN C: Deactivation of macrophages by transforming growth factor-β. Nature 334:260-262, 1988
89. SHARMA K, ZIYADEH FN: The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol 266:F829-F842, 1994
90. COIMBRA T, WIGGINS R, NOH JW, MERRITT S, PHAN SH: Transforming growth factor-β production in anti-glomerular basement membrane disease in the rabbit. Am J Pathol 138:223-234, 1991
91. SHANKLAND SJ, PIPPIN J, PICHLER RH, GORDON KL, FRIEDMAN S, GOLD LI, JOHNSON RJ, COUSER WG: Differential expression of transforming growth factor-β isoforms and receptors in experimental membranous nephropathy. Kidney Int 50:116-124, 1996
92. ISAKA Y, FUJIWARA Y, UEDA N, KANEDA Y, KAMADA T, IMAI E: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest 92:2597-2601, 1993
93. AKAGI Y, ISAKA Y, ARAI M, KANEKO T, TAKENAKA M, MORIYAMA T, KANEDA Y, ANDO A, ORITA Y, KAMADA T, UEDA N, IMAI E: Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 50:I48-155, 1996
94. BORDER WA, OKUDA S, LANGUINO LR, SPORN MB, RUOSLAHTI E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 346:371-374, 1990
95. BORDER WA, NOBLE NA, YAMAMOTO T, HARPER JR, YAMAGUCHI Y, PIERSCHBACHER MD, RUOSLAHTI E: Natural inhibitor ol transforming growth factor-β protects against scarring in experimental kidney disease. Nature 360:361-364, 1992
96. SCHOFCKLMANN HO, RUPPRECHT HD, ZAUNER I, STERZEL RB: TGF-β1-induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-cdk 2 activation and retinoblastoma protein phosphorylation. Kedney Int 51:1228-1236, 1997
97. SÜTÖ TS, FINE LG, KITAMURA M: Mesangial cell-derived transforming growth factor-β1 reduces macrophage adhesiveness with consequent deactivation. Kidney Int 50:445-452, 1996
98. BOGDAN C, PAIK J, VODOVOTZ Y, NATHAN C: Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10. J Biol Chem 267:23301-23308, 1992
99. BOUTARD V, HAVOUIS R, FOUQUERAY B, PHILIPPE C, MOULINOUX J-P, BAUD L: Transforming growth factor-β stimulates orginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol 155:2077-2084, 1995
100. KULKARNI AB, HUH C-G, BECKER, D, GLISER A, LYGHT M, FLANDERS KC, ROBERTS AB, SPORN MB, WARD JM, KARUSSON S: Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90:770-774, 1993
101. KITAMURA M, BURTON S, ENGLISH J, KAWACHI H, FINE LG: Transfer of a mutated gene encoding active transforming growth factor-β1 suppresses mitogenesis and IL-1 response in the glomerulus. Kidney Int 48:1747-1757, 1995
102. FINE LG: Gene transfer into the kidney: Promise for unravelling disease mechanisms, limitations for human gene therapy. Kidney Int 49:612-619, 1996
103. KITAMURA M, SÜTÖ TS: Transfer of genetically engineered macrophages into the glomerulus. Kidney Int 51:1274-1279, 1997
104. KANEDA Y, MORISHITA R, TOMITA N: Increased expression of DNA cointroduced with nuclear protein in adult rat liver. j Mol Med 73:289-297, 1995
105. DZAU VJ, MANN MJ, MORISHITA R, KANEDA Y: Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Nutl Acad Sci USA 93:11421-11425, 1996
106. KITAMURA M: Creation of a reversible on/off system for site-specific in vivo control of exogenous gene activity in the renal glomerulus. Proc Natl Acad Sci USA 93:7387-7391, 1996
107. WANG P, WU P, SIEGEL MI, EGAN RW, BILLAH MM: Interleukin (IL)-10 inhibits nuclear factor κB (NFκB) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 270:9558-9563, 1995
108. KASHIHARA N, MAESHIMA Y, SEKIKAWA T, OKAMOTO K, KANAO K. SUGIYAMA H, MAKINO H, OTA Z, YASUDA T: Inhibition of human mesangial cell proliferation by decoy oligonucleotide targeting the transcription factor, NF-κB. (abstract) J Am Soc Nephrol 6:834, 1995